These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 26250051

  • 21. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
    Fofonka A, Ribeiro JP, Casali KR, Schaan BD.
    Trials; 2014 Nov 04; 15():424. PubMed ID: 25366037
    [Abstract] [Full Text] [Related]

  • 22. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
    Shelbaya S, Rakha S.
    Curr Med Res Opin; 2017 May 04; 33(5):797-801. PubMed ID: 28303721
    [Abstract] [Full Text] [Related]

  • 23. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M, Van Gaal L, Rézette I, Daci E, MacDonald K, Denhaerynck K, Vancayzeele S, De Meester L, Clemens A, Yee B, Abraham I.
    Prim Care Diabetes; 2016 Dec 04; 10(6):425-433. PubMed ID: 27388795
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V, Del Prato S, Araga M, Kothny W.
    Diabetes Obes Metab; 2014 May 04; 16(5):403-9. PubMed ID: 24199686
    [Abstract] [Full Text] [Related]

  • 25. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S.
    Diabetologia; 2007 Jun 04; 50(6):1148-55. PubMed ID: 17387446
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
    Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE.
    Diabetes Obes Metab; 2008 Aug 04; 10(8):675-82. PubMed ID: 18248490
    [Abstract] [Full Text] [Related]

  • 28. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials.
    Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W.
    Diabetes Obes Metab; 2011 Jan 04; 13(1):55-64. PubMed ID: 21114604
    [Abstract] [Full Text] [Related]

  • 29. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C.
    Vasc Health Risk Manag; 2008 Jan 04; 4(4):753-68. PubMed ID: 19065993
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
    Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, Mimori N, Inaba Y, Goodman M.
    Diabetes Res Clin Pract; 2010 Sep 04; 89(3):216-23. PubMed ID: 20537746
    [Abstract] [Full Text] [Related]

  • 31. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD, Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Faria-Neto JR.
    Diabetes Res Clin Pract; 2018 May 04; 139():357-365. PubMed ID: 29596951
    [Abstract] [Full Text] [Related]

  • 32. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
    Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ.
    Cardiovasc Diabetol; 2012 Jan 10; 11():3. PubMed ID: 22234149
    [Abstract] [Full Text] [Related]

  • 33. DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes.
    Kozlovski P, Bhosekar V, Foley JE.
    Vasc Health Risk Manag; 2017 Jan 10; 13():123-126. PubMed ID: 28408838
    [Abstract] [Full Text] [Related]

  • 34. [Safety and efficacy of Vildagliptin in real life Chilean diabetic patients].
    Godoy J G, Gutiérrez V, Montecinos M, Yenes A.
    Rev Med Chil; 2015 Jan 10; 143(1):63-8. PubMed ID: 25860270
    [Abstract] [Full Text] [Related]

  • 35. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    González-Ortiz M, Sánchez-Peña MJ, González-Ortiz LJ, Robles-Cervantes JA, García-Ortega YE, Gómez-Gaitán EA, Pérez-Rubio KG, Martínez-Abundis E.
    Diabetes Technol Ther; 2013 Jul 10; 15(7):564-8. PubMed ID: 23617250
    [Abstract] [Full Text] [Related]

  • 36. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK, Lereun C, Wright D.
    Pharmacology; 2010 Jul 10; 86(1):44-57. PubMed ID: 20616619
    [Abstract] [Full Text] [Related]

  • 37. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE.
    Diabet Med; 2008 Apr 10; 25(4):435-41. PubMed ID: 18341596
    [Abstract] [Full Text] [Related]

  • 38. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
    Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W.
    Diabetes Obes Metab; 2010 Jun 10; 12(6):495-509. PubMed ID: 20518805
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
    Foley JE, Sreenan S.
    Horm Metab Res; 2009 Dec 10; 41(12):905-9. PubMed ID: 19705345
    [Abstract] [Full Text] [Related]

  • 40. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P.
    Clin Ther; 2014 Dec 01; 36(12):2072-2079. PubMed ID: 25453730
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.